BioStem Technologies Earnings Call Transcripts
Fiscal Year 2026
-
The company is transforming into a regenerative medicine platform with a focus on surgical and hospital markets, driven by strategic acquisitions and a robust clinical and IP foundation. Expansion into new markets and internalizing manufacturing are expected to improve margins and support sustained growth.
-
The company is evolving into a diversified regenerative medicine platform, expanding its addressable market through acquisitions and new technologies. Strong clinical evidence, a broadened reimbursement base, and operational investments position it for growth and a potential Nasdaq up-listing.
-
The acquisition of BioTissue's surgical and wound care business doubles the addressable market, expands the product portfolio, and strengthens commercial reach, with $29 million in 2025 sales and 65% gross margins. Integration plans focus on seamless transition, tech transfer, and leveraging synergies for growth and profitability in 2026.
Fiscal Year 2025
-
Q4 2025 revenue was $10.1M with 97% gross margin, but physician office sales declined due to CMS changes. The hospital segment is now the main growth driver, supported by the BioTissue acquisition and expanded product portfolio. Cash runway extends into late Q3 2026.
-
Delivered seventh straight quarter of positive adjusted EBITDA and industry-leading gross margins, despite lower revenue due to pricing pressures. Restated financials had no impact on EBITDA or net income. Positioned for growth with new clinical data, expanded market access, and upcoming CMS reimbursement reform.
-
A medtech firm specializing in placental-based wound care is rapidly expanding through clinical validation, strategic partnerships, and efficient manufacturing. Regulatory changes and new clinical data are expected to shape future growth, with strong financial performance and ongoing M&A opportunities supporting long-term expansion.
-
A proprietary wound care technology platform is driving rapid revenue growth, with strong clinical trial progress and a robust patent portfolio. Anticipated reimbursement changes in 2026 are expected to support further expansion, while new leadership and strategic partnerships position the company for continued success.
-
Q2 2025 saw a 34% revenue decline year-over-year due to reimbursement uncertainty and competition, but gross margins improved to 98.6% and cash rose to $30.8 million. Strategic shifts and clinical progress aim to restore growth amid ongoing regulatory and market headwinds.
-
Record Q1 revenue grew 73% year-over-year to $72.5 million, with strong profitability and cash flow. Commercial momentum for VENDAJE AC continues, despite LCD-related market headwinds and ongoing SEC review for NASDAQ uplisting.
-
A regenerative medicine company achieved record 2024 revenue over $301 million, driven by innovative wound care products and a strategic partnership with Venture Medical. Ongoing clinical trials and a pending Nasdaq uplisting support expansion into new markets and care settings.
Fiscal Year 2024
-
Record revenue and net income were achieved in 2024, driven by strong product launches and market demand. Gross margins remained high, and cash position improved, while ongoing SEC and regulatory matters present some uncertainty. Uplisting to Nasdaq is anticipated soon.
-
Q3 2024 saw record revenue of $82.6M, 95% gross margin, and $9.9M adjusted EBITDA, driven by AmnioWrap2. Cash rose to $14.6M, and clinical trials plus a Nasdaq uplisting are underway, supporting continued growth and market expansion.
-
Four advanced wound care products, processed with proprietary BioRetain technology, are distributed exclusively through Venture Medical, driving rapid revenue growth and market expansion. Ongoing clinical trials and strong retrospective data support payer expansion and product differentiation.
-
Record Q2 revenue and profitability driven by AmnioWrap2, with gross margin at 95% and net income of $6.4M. Strategic initiatives include clinical trials, NASDAQ uplisting, and manufacturing expansion, positioning the company for continued growth despite potential regulatory changes.